Production (Stage)
Fulcrum Therapeutics, Inc.
FULC
$6.85
$0.071.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 99.49% | 90.01% | 81.85% | 79.44% | 8.55% |
| Total Depreciation and Amortization | -29.64% | -26.66% | -23.19% | -18.89% | -14.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.48% | 15.33% | 14.87% | -4.07% | -28.79% |
| Change in Net Operating Assets | 18.67% | 7.91% | -690.32% | 38.35% | 30.16% |
| Cash from Operations | 108.48% | 97.56% | 90.15% | 86.54% | 6.99% |
| Capital Expenditure | 31.51% | 45.28% | 77.33% | 77.78% | 80.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -106.71% | 189.84% | 153.32% | 156.43% | 196.42% |
| Cash from Investing | -107.00% | 187.84% | 152.87% | 155.89% | 194.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -47.36% | -97.68% | -97.50% | -98.84% | -98.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -47.36% | -97.68% | -97.50% | -98.84% | -98.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -58.13% | 443.56% | 170.10% | 954.37% | 274.67% |